Description
Key facts
Sample types:Cell culture extracts, Tissue,
Reacts with:Mouse, Rat, Cow, Human,
Assay type:Sandwich (quantitative),
Assay Platform:Reagents
Product details:
ab109883 (MSP31) is used to quantify the activity of the PDH enzyme complex (pyruvate dehydrogenase) from human, bovine, mouse, and rat samples.
PDH is present in all tissues; it plays a central role in metabolism as it is a key regulatory enzyme that functions at the junction between glycolysis and the tricarboxylic acid cycle. The PDH complex is composed of multiple copies of three catalytic component enzymes; pyruvate dehydrogenase or E1 (EC 1.2.4.1), dihydrolipoamide transacetylase or E2 (EC 2.3.1.12) and dihydrolipoamide dehydrogenase or E3 (EC 1.8.1.4). Inherent to its regulatory function, a number of other proteins regulate PDH activity. One of these, dihydrolipoamide dehydrogenase-binding protein (E3Bp) is necessary for the interaction of the E2 and E3 components.
This dipstick assay kit utilizes two monoclonal antibodies. One recognizes the E2 enzyme (monoclonal antibody bound to the dipstick) and the other antibody (gold-conjugated) recognizes both the E2 and E3Bp components of the PDH complex. The signal intensity is measured by a dipstick reader or analyzed by other imaging systems such as a flatbed scanner. The kit is compatible with a variety of sample types (tissue or cell culture) from a number of different species (human, bovine, mouse, and rat).
All components are stable in their provided containers at room temperature out of direct sunlight.
After diluting the 10X Blocking Buffer to 2X, store at 4°C.
For long-term storage, all buffers can be stored at 4°C.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Pyruvate dehydrogenase (PDH) is an enzyme complex also known as the pyruvate dehydrogenase complex (PDC) or PDH complex. It is a multi-enzyme structure with a mass on the order of megadaltons and plays an important role in cellular energy metabolism. Situated in the mitochondrial matrix pyruvate dehydrogenase converts pyruvate into acetyl-CoA through oxidative decarboxylation. This conversion releases one molecule of CO₂ and reduces NAD+ to NADH. The complex includes three core enzymes: E1 (pyruvate dehydrogenase) E2 (dihydrolipoamide acetyltransferase) and E3 (dihydrolipoamide dehydrogenase).
Biological function summary
The actions of pyruvate dehydrogenase serve as a bridge between glycolysis and the tricarboxylic acid (TCA) cycle. Pyruvate derived from glucose is transformed into acetyl-CoA before entering the TCA cycle for further energy extraction. The PDH complex ensures efficient energy production by tightly regulating the flow of carbon into the TCA cycle. Regulation occurs through phosphorylation by specific PDH kinases which inactivate E1. This mechanism integrates signals from energy status and substrates availability modulating the carbohydrate metabolism.
Pathways
Pyruvate dehydrogenase is a central player in cellular respiration and energy metabolism. It connects glycolytic pathways with the TCA cycle facilitating energy conversion in eukaryotic cells. Key related proteins involve pyruvate kinase (which generates pyruvate) and citrate synthase (which uses acetyl-CoA) ensuring synchronized activity between upstream and downstream metabolic processes. The proper function of PDH activity is necessary for maintaining the metabolic flow with the PDH complex serving a gating role in the energy pathways.
Pyruvate dehydrogenase deficiency results in metabolic challenges as the inability to convert pyruvate efficiently causes an increase in lactate levels. This condition results in lactic acidosis and severe neurological dysfunction. Furthermore alterations in PDH activity are observed in various forms of cancer as cancer cells often rely on aerobic glycolysis (Warburg effect) rather than complete oxidation of glucose. In this context the PDH protein interacts with oncogenic pathways highlighting its role in tumor metabolism and potential therapeutic targeting.
